OBJECTIVES: The aim of this study was to assess public health impact of introducing a new Herpes Zoster (HZ) subunit candidate vaccine (HZ/su), which in clinical studies demonstrated high efficacy against HZ and its complications, in the German populations aged ≥50 and ≥60 years. METHODS: Demographic data were obtained from the German federal statistical office (DeStatis). HZ incidence as well as the proportion of HZ subjects who subsequently developed post-herpetic neuralgia (PHN) was derived from Hillebrand et al. (2014; DOI:0.1016/j.jinf.2014.08.018). Age-specific vaccine efficacy data are based on the results of the phase III efficacy study, published by Lal et al. (2015; DOI:10.1056/NEJMoa1501184), while assuming annual waning rate of the vaccine efficacy of 2% and 4%. The scenarios were explored for the populations aged ≥50 years old and ≥60 years. Coverage of the first dose was assumed to be comparable to the influenza vaccine coverage in these age groups in Germany, with 25% and 36.7% respectively. Compliance of the second dose is assumed to be 100%. A multi-cohort static Markov model that uses an annual cycle length was developed in MS Excelto model the progression of HZ after vaccination (GSK study identifier: HO-16-17270). The cohorts were assessed over their lifetime and the outcomes were compared against no vaccination. RESULTS: Vaccinating 25% of the 34,932,000 adults ≥50 years old with the HZ/su vaccine could potentially prevent between 1,259,138 – 1,622,302 HZ cases and between 226,031 – 295,700 PHN cases, depending on the waning rate assumed. Similarly, when vaccinating 36.7% of the 22,219,000 adults ≥60 years old the vaccine could potentially prevent between 1,121,310 – 1,358,370 HZ cases and 217,636 – 265,578 PHN cases. CONCLUSIONS: The HZ/su vaccine could potentially reduce the HZ-related burden of disease significantly in both age cohorts in Germany.